Dutch Biologic Monitor: Fatigue Among Biologic Recipients Across a Range of Immune-Mediated Inflammatory Diseases

June 3-6, 2020; Virtual Meeting
Overall, 7% of adults self-reported biologic-associated fatigue. Compared with patients not reporting fatigue, they were younger and more frequently smoked, were more likely to have Crohn disease, and used infliximab, rituximab, or vedolizumab.
Format: Microsoft PowerPoint (.ppt)
File Size: 205 KB
Released: August 13, 2020


Provided by Clinical Care Options, LLC

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA

Sophia Kelley

Supported by an educational grant from
AbbVie Inc.
Gilead Sciences, Inc.

Related Content

Clinical Care Options (CCO) expert commentary on new data on IBD pathogenesis and management from the 2021 virtual Crohn’s & Colitis Congress

Anita Afzali, MD, MPH, FACG Released: March 5, 2021

Commentary by Dr. Vinod Chandran on using interleukin inhibitors secukinumab and guselkumab for axial manifestations of psoriatic arthritis, from CCO

Vinod Chandran, MBBS, MD, DM, PhD Physicians: maximum of 0.25 AMA PRA Category 1 Credits Released: January 11, 2021 Expired: January 10, 2022

Commentary from Dr Jim Treat on counseling parents and children about pros and cons of systemic therapy for pediatric plaque psoriasis, from CCO

person default Jim Treat, MD Physicians: maximum of 0.25 AMA PRA Category 1 Credits Released: January 8, 2021 Expired: January 7, 2022

CME for CCO on when to use interleukin inhibitors in psoriatis arthritis: biologic DMARD or MTX naive? IL-17A secukinumab, ixekizumab; IL-12/23 ustekinumab

Vinod Chandran, MBBS, MD, DM, PhD person default Alexis Ogdie, MD, MSCE Physicians: maximum of 0.5 AMA PRA Category 1 Credits Released: December 29, 2020 Expired: December 28, 2021

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.